



US006011062A

United States Patent [19]

[11] Patent Number: **6,011,062**

Schneider et al.

[45] Date of Patent: ***Jan. 4, 2000**

[54]	STORAGE-STABLE PROSTAGLANDIN COMPOSITIONS	5,631,287	5/1997	Schneider	514/530
		5,849,792	12/1998	Schneider	514/530

FOREIGN PATENT DOCUMENTS

[75]	Inventors: L. Wayne Schneider , Crowley, Tex.; Rajan Bawa , Fort Collins, Colo.; Alan L. Weiner , Arlington, Tex.	0 132 027 A1	1/1985	European Pat. Off. .
		0 330 511 A2	6/1989	European Pat. Off. .
		0 407 148 A3	1/1991	European Pat. Off. .
[73]	Assignee: Alcon Laboratories, Inc. , Fort Worth, Tex.	0 418 004 A2	3/1991	European Pat. Off. .
		0 429 248 A2	5/1991	European Pat. Off. .
		0 435 682 A2	7/1991	European Pat. Off. .
[*]	Notice: This patent is subject to a terminal disclaimer.	0 645 145 A3	3/1995	European Pat. Off. .
		0 667 160 A2	8/1995	European Pat. Off. .
		WO85/02841	12/1984	WIPO .
		WO95/05163	2/1995	WIPO .
[21]	Appl. No.: 09/246,072	WO97/29752	8/1997	WIPO .
[22]	Filed: Feb. 9, 1999	WO98/41208	9/1998	WIPO .

OTHER PUBLICATIONS

[63] Continuation-in-part of application No. 09/033,748, Feb. 24, 1998, abandoned, which is a continuation-in-part of application No. 08/738,629, Oct. 29, 1996, Pat. No. 5,849,792, which is a division of application No. 08/362,677, Dec. 22, 1994, Pat. No. 5,631,287.

[51] **Int. Cl.**⁷ **A61K 31/557**

[52] **U.S. Cl.** **514/530; 514/570; 514/571; 514/573**

[58] **Field of Search** 514/530, 573

Attwood and Florence, "Reactivity in surfactant systems," *Surfactant Systems, Their Chemistry, Pharmacy and Biology*, 11:698-777, Chapman and Hall, Publ.

Foster et al., "Intraocular Penetration of Miconazole in Rabbits," *Arch. Ophthalmol.* 97/9, pp. 1703-1706 (1979) (abstract only).

Sayed and Repta, "Solubilization and stabilization of an investigational antineoplastic drug (NSC NO. 278214) in an intravenous formulation using an emulsion vehicle," *Interna'l J. of Pharmaceutics*, vol. 13 (1983), pp. 302-312.

Primary Examiner—Robert Gerstl
Attorney, Agent, or Firm—Patrick M. Ryan

References Cited

U.S. PATENT DOCUMENTS

4,075,333	2/1978	Joose	424/237
4,960,799	10/1990	Nagy	514/567
5,098,606	3/1992	Nakajima et al.	252/358
5,110,493	5/1992	Cherng-Chyi et al.	514/413
5,185,372	2/1993	Ushio et al.	514/552
5,627,209	5/1997	DeSantis, Jr. et al.	514/530

[57] ABSTRACT

The use of polyethoxylated castor oils in prostaglandin compositions enhances the prostaglandin's chemical stability.

20 Claims, 3 Drawing Sheets

FIG. 1

Stability of Compound No. 2. at 65°C in pH 5.0
Preserved Vehicle with Cremophor® EL.

- 5% Cremophor® EL / 0.01% Compound No. 2.
- ◇ 0.5% Cremophor® EL / 0.01% Compound No. 2.
- 0.5% Cremophor® EL / 0.001% Compound No. 2.
- △ 0.05% Cremophor® EL / 0.001% Compound No. 2.




FIG. 2

Stability of 0.01% Compound No. 2. at 55°C in pH 5.0 Preserved Vehicle with the indicated Surfactant.

- 0.5% Cremophor® EL
- △ 0.5% Alkamuls® EL-620
- ◇ Polysorbate 80





FIG. 3

Stability of 0.01% Compound No. 2. at 55°C in pH 7.4 Preserved Vehicle with the indicated Surfactant.

- 0.5% Cremophor® EL
- △ 0.5% Alkamuls® EL-620
- ◇ 0.5% Polysorbate 80



STORAGE-STABLE PROSTAGLANDIN COMPOSITIONS

This is a continuation-in-part application of U.S. patent application Ser. No. 09/033,748, filed Feb. 24, 1998, which is a continuation-in-part application of U.S. patent application Ser. No. 08/738,629, filed Oct. 29, 1996, now U.S. Pat. No. 5,849,792, which is a divisional application of U.S. patent application Ser. No. 08/362,677, filed on Dec. 22, 1994, now U.S. Pat. No. 5,631,287.

BACKGROUND OF THE INVENTION

The present invention relates generally to prostaglandin compositions. In particular, the present invention relates to storage stable, pharmaceutical compositions containing prostaglandins and surfactants. As used herein, the term "prostaglandin" or "PG" shall refer to prostaglandins and derivatives and analogues thereof including pharmaceutically acceptable salts and esters, except as otherwise indicated by context.

Prostaglandins have notoriously low water solubility, and are generally unstable. Attempts have been made to solubilize and stabilize various prostaglandins by complexing them with different cyclodextrins. See, for example: EP 330 511 A2 (Ueno et al.) and EP 435 682 A2 (Wheeler). These attempts have met with varying success.

Surfactants and/or solubilizers have been used with other types of drugs having low water solubility. However, the addition of surfactants and/or solubilizers may enhance or adversely affect the chemical stability of drug compounds. See *Surfactant Systems, Their Chemistry, Pharmacy, and Biology*, (eds. Attwood et al.), Chapman and Hall, New York, 1983, Ch. 11, particularly pp. 698-714.

The use of non-ionic surfactants, such as polyethoxylated castor oils, as solubilizing agents is known. See, for example, U.S. Pat. No. 4,960,799 (Nagy).

The use of non-ionic surfactants such as polyethoxylated castor oils in stable emulsions is also known. U.S. Pat. No. 4,075,333 (Josse) discloses stable, intravenous emulsion formulations of vitamins. El-Sayed et al., *Int J. Pharm.*, 13:303-12 (1983) discloses stable oil-in-water emulsions of an antineoplastic drug. U.S. Pat. No. 5,185,372 (Ushio et al.) discloses topically administrable ophthalmic formulations of vitamin A which are stable preparations in which a non-ionic surfactant is used to form an emulsion of vitamin A in an aqueous medium.

What is needed is a commercially viable, storage-stable prostaglandin composition.

SUMMARY OF THE INVENTION

The present invention is directed to the use of polyethoxylated castor oils in pharmaceutical compositions containing prostaglandins. It has now been unexpectedly discovered that the use of polyethoxylated castor oils in such compositions enhances the chemical stability of prostaglandins. The compositions of the present invention can be administered to the body in a variety of ways. When topically applied to the eye, the compositions of the present invention provide both initial and continual comfort.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the stabilizing effect at different concentrations of a polyethoxylated castor oil in a preserved prostaglandin formulation at pH 5.0.

FIG. 2 compares the stabilizing effect of different surfactants in a preserved prostaglandin formulation at pH 5.0.


FIG. 3 compares the stabilizing effect of different surfactants in a preserved prostaglandin formulation at pH 7.4.

DETAILED DESCRIPTION OF THE INVENTION


Prostaglandin esters are difficult to formulate in storage-stable solutions as they tend to be hydrolytically unstable. In some instances, the parent acids of some prostaglandin esters are also unstable. The pharmaceutical compositions of the present invention, however, are storage stable. These compositions contain a prostaglandin and a stability-enhancing amount of a polyethoxylated castor oil.

The polyethoxylated castor oils useful in the compositions of the present invention are commercially available, and include those classified as PEG-2 to PEG-200 castor oils, as well as those classified as PEG-5 to PEG-200 hydrogenated castor oils. Such polyethoxylated castor oils include those manufactured by Rhone-Poulenc (Cranbury, N.J.) under the Alkamuls® brand, those manufactured by BASF (Parsippany, N.J.) under the Cremophor® brand, and those manufactured by Nikko Chemical Co., Ltd. (Tokyo, Japan) under the Nikkol brand. Preferred polyethoxylated castor oils are those classified as PEG-15 to PEG-50 castor oils, and more preferred are PEG-30 to PEG-35 castor oils. It is most preferred to use those polyethoxylated castor oils known as Cremophor® EL and Alkamuls® EL-620. Preferred polyethoxylated hydrogenated castor oils are those classified as PEG-25 to PEG-55 hydrogenated castor oils. The most preferred polyethoxylated hydrogenated castor oil is PEG40 hydrogenated castor oil, such as Nikkol HCO40.


The terms "prostaglandin" and "PG" are generally used to describe a class of compounds which are analogues and derivatives of prostanic acid (1):



PG's may be further classified, for example, according to their 5-membered ring structure, using a letter designation:



Prostaglandins of the A series (PGA's):



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.